Research Article| Volume 32, ISSUE 4, P710-713, April 2010

Outpatient treatment of propionic acidemia-associated hyperammonemia with N-carbamoyl-l-glutamate in an infant

      This paper is only available as a PDF. To read, Please Download here.


      Objective: The aim of this research letter was to describe the use of N-carbamoyl-l-glutamate as first-line treatment of hyperammonemia in a 4-month-old female patient with propionic acidemia (PA).
      Methods: A 4-month-old female patient weighing 3.9 kg presented with decompensation with PA and initial hyperammonemia of 451 μg/dL. The patient was receiving a protein-restricted diet supplemented with l-carnitine at a dosage of 100 mg/kg/d during 2 consecutive months. Treatment with N-carbamoyl-l-glutamate was administered during 4 days on an outpatient basis at a dosage of 100 mg/kg/d, representing a dosage of 200 mg BID. The patient's hyperammonemia was monitored for 1 week.
      Results: The patient's ammonia concentration started to decrease on the first day of the initiation of the treatment with N-carbamoyl-l-glutamate, from 451 to 68 μg/dL (normal range, 10-80 μg/dL) at day 6 of follow-up. The patient did not require intravenous fluids, invasive procedures, or hospitalization.
      Conclusion:N-carbamoyl-l-glutamate, combined with a protein-restricted diet and l-carnitine supplementation, was apparently effective as first-line treatment of hyperammonemia in this infant with PA.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Fernandes J Saudubray JM Berge GV Walter JH Inborn Metabolic Diseases: Diagnosis and Treatment. 4th ed. Springer, Heidelberg, Germany2006
        • Deodato F
        • Boenzi S
        • Santorelli FM
        • Dionisi-Vici C
        Methylmalonic and propionic aciduria.
        Am J Med Genet C Semin Med Genet. 2006; 142C: 104-112
        • Ogier de Baulny H
        • Saudubray JM
        Branched-chain organic acidurias.
        Semin Neonatol. 2002; 7: 65-74
        • Wendel U
        • Eissler A
        • Sperl W
        • Schadewaldt P
        On the differences between urinary metabolite excretion and odd-numbered fatty acid production in propionic and methylmalonic acidaemias.
        J Inherit Metab Dis. 1995; 18: 584-591
        • Leonard JV
        The management and outcome of propionic and methylmalonic acidaemia.
        J Inherit Metab Dis. 1995; 18: 430-434
      2. Siegel GJ Albers RW Brady ST Price DL Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. 7th ed. Elsevier, Boston, Mass2006
        • Touati G
        • Valayannopoulos V
        • Mention K
        • et al.
        Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture.
        J Inherit Metab Dis. 2006; 29: 288-298
        • de Baulny HO
        • Benoist JF
        • Rigal O
        • et al.
        Methylmalonic and propionic acidaemias: Management and outcome.
        J Inherit Metab Dis. 2005; 28: 415-423
        • Butterworth RF
        Effects of hyperammonaemia on brain function.
        J Inherit Metab Dis. 1998; 21: 6-20
        • Prietsch V
        • Lindner M
        • Zschocke J
        • et al.
        Emergency management of inherited metabolic diseases.
        J Inherit Metab Dis. 2002; 25: 531-546
      3. McMillan JA Feigin RD DeAngelis CD Jones MD Oski's Pediatrics: Principles & Practice. 4th ed. Lippincott, Williams & Wilkins, Philadelphia, Pa2006
        • Coude FX
        • Sweetman L
        • Nyhan WL
        Inhibition by propionylcoenzyme A of N-acetylglutamate synthetase in rat liver mitochondria: A possible explanation for hyperammonemia in propionic and methylmalonic acidemia.
        J Clin Invest. 1979; 64: 1544-1551
        • Kim S
        • Paik WK
        • Cohen PP
        Ammonia intoxication in rats: Protection by N-carbamoyl--l-glutamate plus -l-arginine.
        Proc Natl Acad Sci U S A. 1972; 69: 3530-3533
        • Bachmann C
        • Colombo JP
        • Jaggi K
        N-acetylglutamate synthetase (NAGS) deficiency: Diagnosis, clinical observations and treatment.
        Adv Exp Med Biol. 1982; 153: 39-45
        • Schubiger G
        • Bachmann C
        • Barben P
        • et al.
        N-acetylglutamate synthetase deficiency: Diagnosis, management and follow-up of a rare disorder of ammonia detoxication.
        Eur J Pediatr. 1991; 150: 353-356
        • Coude FX
        • Ogier H
        • Grimber G
        • et al.
        Correlation between blood ammonia concentration and organic acid accumulation in isovaleric and propionic acidemia.
        Pediatrics. 1982; 69: 115-117
        • Levrat V
        • Forest I
        • Fouilhoux A
        • et al.
        Carglumic acid: An additional therapy in the treatment of organic acidurias with hyperammonemia?.
        Orphanet J Rare Dis. 2008; 3: 2
        • Gebhardt B
        • Dittrich S
        • Parbel S
        • et al.
        N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia.
        J Inherit Metab Dis. 2005; 28: 241-244
      4. Zschocke J Hoffmann G Vademecum Metabolicum. 2nd ed. CPI Books, Clausen & Bosse GmbH, Leck, Germany2004
        • Schwahn BC
        • Pieterse L
        • Bisset WM
        • et al.
        Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia.
        Eur J Pediatr. 2010; 169: 133-134